These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28552868)

  • 1. [Delays in clinical development of neurological drugs in Japan].
    Ikeda M
    Rinsho Shinkeigaku; 2017 Jun; 57(6):274-279. PubMed ID: 28552868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delays in neurological drug development in Japan.
    Shimazawa R; Ikeda M
    Intern Med; 2011; 50(15):1565-8. PubMed ID: 21804282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delays in psychiatric drug development in Japan.
    Shimazawa R; Kusumi I; Ikeda M
    J Clin Pharm Ther; 2012 Jun; 37(3):348-51. PubMed ID: 22017294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
    Honig PK
    Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E; Masuda S; Kimura H
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.
    Matsuda K; Nagai S; Sugimoto K
    Jpn J Clin Oncol; 2023 Dec; 53(12):1125-1129. PubMed ID: 37642224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
    Maeda H; Kurokawa T
    Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the success rates of new drug development in Japan and the lag behind the US.
    Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
    Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Insights into neurological drug development in Japan].
    Nakamura H; Uyama Y
    Brain Nerve; 2012 Mar; 64(3):229-35. PubMed ID: 22402716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Participation to international registration trials--from the investigator's standpoint].
    Ohtsu A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):297-300. PubMed ID: 17301548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A historical review on International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) and internationalization of Japan's new drugs development and regulation].
    Kurokawa T
    Yakushigaku Zasshi; 2014; 49(2):165-70. PubMed ID: 25799837
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between drug lag and factors associated with clinical trials in Japan.
    Ohwaki K; Nakabayashi T
    J Clin Pharm Ther; 2014 Dec; 39(6):649-52. PubMed ID: 25200123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
    Shimazawa R; Ikeda M
    Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan.
    Ueno T; Asahina Y; Tanaka A; Yamada H; Nakamura M; Uyama Y
    Clin Pharmacol Ther; 2014 May; 95(5):533-41. PubMed ID: 24213186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.